Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer

Rhodes,Lyndsay  V.; Tilghman,Syreeta  L.; Boue,Stephen  M.; Wang,Shuchun; Khalili,Hafez; Muir,Shannon  E.; Bratton,Melyssa  R.; Zhang,Qiang; Wang,Guangdi; Burow,Matthew  E.; Collins-Burow,Bridgette  M.

doi:10.3892/ol.2011.460

Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer

Authors:
- Lyndsay V. Rhodes
- Syreeta L. Tilghman
- Stephen M. Boue
- Shuchun Wang
- Hafez Khalili
- Shannon E. Muir
- Melyssa R. Bratton
- Qiang Zhang
- Guangdi Wang
- Matthew E. Burow
- Bridgette M. Collins-Burow
View Affiliations

Affiliations: Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA, United States Department of Agriculture, Xavier University of Louisiana, New Orleans, LA 70125, USA, Department of Pharmacology, Tulane University Health Sciences Center, New Orleans, LA 70112, USA, RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA, RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA
Published online on: October 24, 2011 https://doi.org/10.3892/ol.2011.460
Pages: 163-171

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of this study was to investigate the effects of glyceollins on the suppression of tumorigenesis in triple‑negative breast carcinoma cell lines. We further explored the effects of glyceollins on microRNA and protein expression in MDA‑MB‑231 cells. Triple‑negative (ER‑, PgR‑ and Her2/neu‑) breast carcinoma cells were used to test the effects of glyceollins on tumorigenesis in vivo. Following this procedure, unbiased microarray analysis of microRNA expression was performed. Additionally, we examined the changes in the proteome induced by glyceollins in the MDA‑MB‑231 cells. Tumorigenesis studies revealed a modest suppression of MDA‑MB‑231 and MDA‑MB‑468 cell tumor growth in vivo. In response to glyceollins we observed a distinct change in microRNA expression profiles and proteomes of the triple‑negative breast carcinoma cell line, MDA‑MB‑231. Our results demonstrated that the glyceollins, previously described as anti‑estrogenic agents, also exert antitumor activity in triple‑negative breast carcinoma cell systems. This activity correlates with the glyceollin alteration of microRNA and proteomic expression profiles.

View Figures

View References

1	Reis-Filho JS and Tutt AN: Triple negative tumours: a critical review. Histopathology. 52:108–118. 2008. View Article : Google Scholar
2	Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 7:962006. View Article : Google Scholar : PubMed/NCBI
3	Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progeste- rone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a popu- lation-based study from the California cancer registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar
4	Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
5	Gail MH, Anderson WF, Garcia-Closas M and Sherman ME: Absolute risk models for subtypes of breast cancer. J Natl Cancer Inst. 99:1657–1659. 2007. View Article : Google Scholar : PubMed/NCBI
6	Reis-Filho JS, Westbury C and Pierga JY: The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol. 59:225–231. 2006. View Article : Google Scholar : PubMed/NCBI
7	Messina M: A brief historical overview of the past two decades of soy and isoflavone research. J Nutr. 140:1350S–1354S. 2010. View Article : Google Scholar : PubMed/NCBI
8	Murkies AL, Wilcox G and Davis SR: Clinical review 92: Phytoestrogens. J Clin Endocrinol Metab. 83:297–303. 1998. View Article : Google Scholar : PubMed/NCBI
9	Tham DM, Gardner CD and Haskell WL: Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab. 83:2223–2235. 1998.PubMed/NCBI
10	Humfrey CD: Phytoestrogens and human health effects: weighing up the current evidence. Nat Toxins. 6:51–59. 1998. View Article : Google Scholar : PubMed/NCBI
11	Collins-Burow BM, Burow ME, Duong BN and McLachlan JA: Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms. Nutr Cancer. 38:229–244. 2000. View Article : Google Scholar
12	Collins BM, McLachlan JA and Arnold SF: The estrogenic and antiestrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast. Steroids. 62:365–372. 1997. View Article : Google Scholar : PubMed/NCBI
13	Fournier DB, Erdman JW Jr and Gordon GB: Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. Cancer Epidemiol Biomarkers Prev. 7:1055–1065. 1998.PubMed/NCBI
14	Barnes S: The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res Treat. 46:169–179. 1997. View Article : Google Scholar : PubMed/NCBI
15	Lamartiniere CA, Zhang JX and Cotroneo MS: Genistein studies in rats: potential for breast cancer prevention and reproductive and developmental toxicity. Am J Clin Nutr. 68:1400S–1405S. 1998.PubMed/NCBI
16	Diel P, Smolnikar K, Schulz T, Laudenbach-Leschowski U, Michna H and Vollmer G: Phytoestrogens and carcinogenesis-differential effects of genistein in experimental models of normal and malignant rat endometrium. Hum Reprod. 16:997–1006. 2001. View Article : Google Scholar : PubMed/NCBI
17	Boue SM, Carter CH, Ehrlich KC and Cleveland TE: Induction of the soybean phytoalexins coumestrol and glyceollin by Aspergillus. J Agric Food Chem. 48:2167–2172. 2000. View Article : Google Scholar : PubMed/NCBI
18	Bhattacharyya M and Ward EWB: Resistance, susceptibility and accumulation of glyceollins I-III in soybean organs inoculated with Phytophthora megasperma f. sp. Glycinea. Physiol and Mol Plant Pathol. 29:227–237. 1986. View Article : Google Scholar
19	Boue SM, Wiese TE, Nehls S, Burow ME, Elliott S, Carter-Wientjes CH, Shih BY, McLachlan JA and Cleveland TE: Evaluation of the estrogenic effects of legume extracts containing phytoestrogens. J Agric Food Chem. 51:2193–2199. 2003. View Article : Google Scholar : PubMed/NCBI
20	Graham TL and Graham MY: Glyceollin elicitors induce major but distinctly different shifts in isoflavonoid metabolism in proximal and distal soybean cell populations. Mol Plant Microbe Interact. 4:60–68. 1991. View Article : Google Scholar
21	Burow ME, Boue SM, Collins-Burow BM, et al: Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor alpha and beta. J Clin Endocrinol Metab. 86:1750–1758. 2001.
22	Salvo VA, Boue SM, Fonseca JP, et al: Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res. 12:7159–7164. 2006. View Article : Google Scholar : PubMed/NCBI
23	Rhodes LV, Muir SE, Elliott S, et al: Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat. 121:293–300. 2010. View Article : Google Scholar : PubMed/NCBI
24	Burow ME, Tang Y, Collins-Burow BM, et al: Effects of environmental estrogens on tumor necrosis factor alpha-mediated apoptosis in MCF-7 cells. Carcinogenesis. 20:2057–2061. 1999. View Article : Google Scholar : PubMed/NCBI
25	Gao X, Gulari E and Zhou X: In situ synthesis of oligonucleotide microarrays. Biopolymers. 73:579–596. 2004. View Article : Google Scholar : PubMed/NCBI
26	Zhu Q, Hong A, Sheng N, et al: microParaflo biochip for nucleic acid and protein analysis. Methods Mol Biol. 382:287–312. 2007. View Article : Google Scholar : PubMed/NCBI
27	Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI
28	Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar
29	Winter J and Diederichs S: MicroRNA biogenesis and cancer. Methods Mol Biol. 676:3–22. 2011. View Article : Google Scholar
30	Allen KE and Weiss GJ: Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther. 9:3126–3136. 2011. View Article : Google Scholar : PubMed/NCBI
31	Gandellini P, Profumo V, Folini M and Zaffaroni N: MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin Ther Targets. 15:265–279. 2011. View Article : Google Scholar : PubMed/NCBI
32	Nana-Sinkam SP and Croce CM: MicroRNA dysregulation in cancer: opportunities for the development of microRNA-based drugs. IDrugs. 13:843–846. 2011.PubMed/NCBI
33	Ma L and Weinberg RA: MicroRNAs in malignant progression. Cell Cycle. 7:570–572. 2008. View Article : Google Scholar
34	O'Day E and Lal A: MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 12:2012011.
35	Gregory PA, Bracken CP, Bert AG and Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle. 7:3112–3118. 2008. View Article : Google Scholar : PubMed/NCBI
36	Korpal M and Kang Y: The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol. 5:115–119. 2008. View Article : Google Scholar : PubMed/NCBI
37	Chen J, Wang L, Matyunina LV, Hill CG and McDonald JF: Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol. 121:200–205. 2011. View Article : Google Scholar : PubMed/NCBI
38	Tryndyak VP, Beland FA and Pogribny IP: E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer. 126:2575–2583. 2011.PubMed/NCBI
39	Ota D, Mimori K, Yokobori T, et al: Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients. Int J Oncol. 38:955–962. 2011.PubMed/NCBI
40	Patel JB, Appaiah HN, Burnett RM, et al: Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene. 30:1290–1301. 2011. View Article : Google Scholar : PubMed/NCBI
41	Li J, Liang S, Yu H, Zhang J, Ma D and Lu X: An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. Gynecol Oncol. 119:543–548. 2011. View Article : Google Scholar : PubMed/NCBI
42	Li J, Liang SH and Lu X: Potential role of ezrin and its related microRNA in ovarian cancer invasion and metastasis. Zhonghua Fu Chan Ke Za Zhi. 45:787–792. 2011.PubMed/NCBI
43	Wu N, Zhao X, Liu M, et al: Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PLoS One. 6:e162642011. View Article : Google Scholar : PubMed/NCBI
44	Liu XX, Li XJ, Zhang B, et al: MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett. 585:1363–1367. 2011. View Article : Google Scholar : PubMed/NCBI
45	Martinez I, Cazalla D, Almstead LL, Steitz JA and DiMaio D: miR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci USA. 108:522–527. 2011. View Article : Google Scholar : PubMed/NCBI
46	Villarreal G Jr, Oh DJ, Kang MH and Rhee DJ: Coordinated Regulation of Extracellular Matrix Synthesis by the MicroRNA-29 Family in the Trabecular Meshwork. Invest Ophthalmol Vis Sci. 52:3391–3397. 2011. View Article : Google Scholar : PubMed/NCBI
47	Maurer B, Stanczyk J, Jungel A, et al: MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 62:1733–1743. 2011. View Article : Google Scholar : PubMed/NCBI
48	Li Z, Hassan MQ, Jafferji M, et al: Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem. 284:15676–15684. 2009. View Article : Google Scholar : PubMed/NCBI
49	Ott CE, Grunhagen J, Jager M, et al: MicroRNAs differentially expressed in postnatal aortic development downregulate elastin via 3′ UTR and coding-sequence binding sites. PLoS One. 6:e162502011.PubMed/NCBI
50	Mott JL, Kobayashi S, Bronk SF and Gores GJ: mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI
51	Park SY, Lee JH, Ha M, Nam JW and Kim VN: miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol. 16:23–29. 2009. View Article : Google Scholar : PubMed/NCBI
52	Hashimoto Y, Akiyama Y, Otsubo T, Shimada S and Yuasa Y: Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis. 31:777–784. 2011. View Article : Google Scholar : PubMed/NCBI
53	Li D, Zhao Y, Liu C, et al: Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 7:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
54	Wang X, Wang J, Ma H, Zhang J and Zhou X: Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol. March 10–2011.(E-pub ahead of print).
55	Sekiya Y, Ogawa T, Iizuka M, Yoshizato K, Ikeda K and Kawada N: Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon-beta-induced inhibition of hepatic stellate cell proliferation. J Cell Physiol. 226:2535–2542. 2011. View Article : Google Scholar : PubMed/NCBI
56	Liu L, Chen L, Xu Y, Li R and Du X: microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun. 400:236–240. 2011. View Article : Google Scholar : PubMed/NCBI
57	Tili E, Michaille JJ, Adair B, et al: Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis. 31:1561–1566. 2011. View Article : Google Scholar : PubMed/NCBI
58	Pan J, Hu H, Zhou Z, et al: Tumor-suppressive mir-663 gene induces mitotic catastrophe growth arrest in human gastric cancer cells. Oncol Rep. 24:105–112. 2011.PubMed/NCBI
59	Zhang X, Yu H, Lou JR, et al: MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem. 286:1429–1435. 2011. View Article : Google Scholar : PubMed/NCBI
60	Ory B, Ramsey MR, Wilson C, et al: A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest. 121:809–820. 2011. View Article : Google Scholar : PubMed/NCBI
61	Du L, Schageman JJ, Subauste MC, et al: miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res. 7:1234–1243. 2009. View Article : Google Scholar : PubMed/NCBI
62	Arndt GM, Dossey L, Cullen LM, et al: Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer. 9:3742009. View Article : Google Scholar : PubMed/NCBI
63	Li Q, Wang G, Shan JL, et al: MicroRNA-224 is upregulated in HepG2 cells and involved in cellular migration and invasion. J Gastroenterol Hepatol. 25:164–171. 2011. View Article : Google Scholar : PubMed/NCBI
64	Mees ST, Mardin WA, Sielker S, et al: Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol. 16:2339–2350. 2009. View Article : Google Scholar : PubMed/NCBI
65	Wingett DG, Vestal RE, Forcier K, Hadjokas N and Nielson CP: CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat. 50:27–36. 1998. View Article : Google Scholar : PubMed/NCBI
66	Castilla MA, Moreno-Bueno G, Romero-Perez L, et al: Micro- RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol. 223:72–80. 2011. View Article : Google Scholar : PubMed/NCBI
67	Bonci D: MicroRNA-21 as therapeutic target in cancer and cardiovascular disease. Recent Pat Cardiovasc Drug Discov. 5:156–161. 2011. View Article : Google Scholar : PubMed/NCBI
68	Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA and Stathopoulos EN: MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 10:507–517. 2011. View Article : Google Scholar : PubMed/NCBI
69	Mei M, Ren Y, Zhou X, et al: Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat. 9:77–86. 2011. View Article : Google Scholar : PubMed/NCBI
70	Gong C, Yao Y, Wang Y, et al: Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem. 286:19127–19137. 2011. View Article : Google Scholar : PubMed/NCBI
71	Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
72	Qi L, Bart J, Tan LP, et al: Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 9:1632009. View Article : Google Scholar : PubMed/NCBI
73	Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A and Lund AH: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 283:1026–1033. 2008. View Article : Google Scholar : PubMed/NCBI
74	Song B, Wang C, Liu J, et al: MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res. 29:292010. View Article : Google Scholar : PubMed/NCBI
75	Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 282:14328–14336. 2007. View Article : Google Scholar : PubMed/NCBI
76	Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
77	Russell RL, Pedersen AN, Kantor J, et al: Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines. Br J Cancer. 78:710–717. 1998. View Article : Google Scholar : PubMed/NCBI
78	Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW and Waltham M: Vimentin and epithelial-mesenchymal transition in human breast cancer – observations in vitro and in vivo. Cells Tissues Organs. 185:191–203. 2007.
79	Joglekar MV, Patil D, Joglekar VM, et al: The miR-30 family microRNAs confer epithelial phenotype to human pancreatic cells. Islets. 1:137–147. 2009. View Article : Google Scholar : PubMed/NCBI